GOP Senator Probes FDA Over Rare Disease Drug Rejections

Senator Ron Johnson’s decision to launch a formal investigation into the Food and Drug Administration (FDA) represents a pivotal moment in the intersection of federal policy and biotechnology. By focusing specifically on the agency’s handling of biologic therapies for Duchenne muscular dystrophy (DMD) and other rare, life-threatening conditions, Johnson is reopening a long-standing wound in the drug approval process: the tension between rigorous clinical evidence and the desperate timelines of patients with terminal illnesses. This investigation is not merely a procedural inquiry; it is a direct challenge to the FDA’s traditional evidentiary standards, which critics argue are ill-suited for the era of precision medicine and orphan drugs.

The context of this probe is deeply rooted in Johnson’s legislative history, most notably his role as a primary architect of the Right to Try Act. That legislation was designed to bypass certain FDA hurdles for terminally ill patients, and this new investigation suggests that the Senator believes the agency has not fully embraced the spirit of that law in its broader approval processes. The focus on DMD is particularly strategic. The DMD community has been one of the most vocal and organized patient advocacy groups in history, famously influencing the 2016 approval of Sarepta Therapeutics’ Exondys 51 despite internal FDA disagreement. By centering the investigation on DMD, Johnson is tapping into a pre-existing reservoir of public and political frustration regarding the pace of biologic approvals.

“

Senator Ron Johnson’s decision to launch a formal investigation into the Food and Drug Administration (FDA) represents a pivotal moment in the intersection of federal policy and biotechnology.

The inclusion of FDA Commissioner Marty Makary in these discussions is equally significant. Makary, who has historically been viewed as a reformer, now finds himself in the crosshairs of a Republican-led inquiry that seeks to push the agency toward more flexibility. The investigation will likely scrutinize the Center for Biologics Evaluation and Research (CBER), the division responsible for overseeing the complex gene therapies and biologics that dominate the rare disease pipeline. If Johnson’s probe uncovers evidence of what he terms unnecessary rejections, it could lead to legislative efforts to mandate more lenient surrogate endpoint usage in rare disease trials—a move that would fundamentally alter the risk-reward calculus for biotech investors.